Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Druggable genome CRISPRi screen in hydrogels reveals regulators of cortactin-driven actin remodeling promoting glioblastoma invasion
Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi
Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi
View: Text | PDF
Research Article Cell biology Oncology

Druggable genome CRISPRi screen in hydrogels reveals regulators of cortactin-driven actin remodeling promoting glioblastoma invasion

  • Text
  • PDF
Abstract

To identify therapeutic targets limiting glioblastoma invasion, we applied druggable genome CRISPRi screens and multiomic analysis to patient-derived glioblastoma cells in micro-dissectible biomimetic 3D hydrogels that permitted separation and analysis of core versus invasive fractions. Of 2,550 genes screened, 12 encoded druggable targets whose suppression limited invasion, of which AURKB (encoding aurora kinase B) and ACP1 (encoding low molecular weight protein tyrosine phosphatase, LMW-PTP) were validated in neurosphere assays and in vivo. Proximity labeling identified cortactin as a link between LMW-PTP and aurora B, and we observed that cortactin underwent serine phosphorylation by aurora B and tyrosine dephosphorylation by LMW-PTP. Targeting ACP1 or AURKB via CRISPRi or inhibitors in culture and in vivo shifted the cortactin phosphorylation balance in glioblastoma, reducing levels of cortactin and the actin-related protein 2/3 (Arp2/3) complex that mediates cortactin-induced actin stabilization, thereby reducing actin-cortactin-Arp2/3 colocalization and subsequent actin polymerization. AURKB or ACP1 targeting shifted actin from cytoplasm to the nucleus, reducing mesenchymal gene expression. Biophysical analysis implicated AURKB in glioblastoma cell adhesion and stiffness needed for initial migration and ACP1 in mechanical stress resistance required for later migration. These findings revealed a targetable axis balancing kinase and phosphatase activities to regulate actin polymerization during glioblastoma invasion.

Authors

Mufeng Hu, Anna Weldy, Isabella M. Lovalvo, Erin A. Akins, Saket Jain, Alexander Chang, Ankita Sati, Meeki Lad, Austin Lui, Akhil Rajidi, Ameya Kothekar, Erika A. Ding, Juan A. Oses Prieto, Pablo Estevez, Alma L. Burlingame, Sanjay Kumar, Manish K. Aghi

×

Figure 7

Targeting AURKB and ACP1 in orthotopic GBM xenografts in vivo slows invasion and uncouples cortactin from actin in tumor cells without affecting survival.

Options: View larger image (or click on image) Download as PowerPoint
Targeting AURKB and ACP1 in orthotopic GBM xenografts in vivo slows inva...
GBM43/sgGAL4, GBM43/sgAURKB, GBM43/sgACP1, and GBM43/sgCTTN cells were implanted into right frontal lobes of athymic mice and grew until mice reached endpoint. (A) GBM43/sgAURKB (P = 0.02; n = 7) and GBM43/sgCTTN (P = 0.02; n = 4) xenografts were less invasive than GBM43/sgGAL4 (n = 6) in image fractal analysis of tumors and surrounding brain, yielding fractal dimension, a measure of invasive tumor growth between 1 and 2; higher numbers represent greater invasiveness. GBM43/sgACP1 (n = 6) xenografts exhibited no fractal dimension change versus GBM43/sgGAL4 xenografts (P = 0.8). Image composites at original magnification ×20; scale bar: 500 mm. (B) No difference noted in survival of mice with GBM43/sgGAL4, GBM43/sgAURKB, GBM43/sgACP1, and GBM43/sgCTTN xenografts (P = 0.6, n = 6–10/group). (C) Maximal cross-sectional tumor area at endpoint was smaller in GBM43/sgACP1 (n = 9, P = 0.007) and GBM43/sgCTTN (n = 6, P = 0.03) xenografts versus GBM43/sgGAL4 (n = 6) xenografts, but unchanged in GBM43/sgAURKB (n = 7) xenografts versus GBM43/sgGAL4 (P = 0.08). One-way ANOVA with Tukey’s pairwise post hoc comparisons. (D) Intratumoral cell density, assessed by counting cell number in 3–5 identical fields, was higher in GBM43/sgACP1 (P = 0.02) or GBM43/sgCTTN (P = 0.03) xenografts versus GBM43/sgGAL4 xenografts, but unchanged in GBM43/sgAURKB (P = 0.9) xenografts. n = 5 tumors/group, original magnification, ×60; scale bar: 50 mm. (E) Xenograft endpoint immunofluorescence revealed decreased immunopositive cortactin area normalized to total cellular tumor area in GBM43/sgAURKB (P = 0.003) and GBM43/sgACP1 (P = 0.005) xenografts versus GBM43/sgGAL4 xenografts (upper graph) and increased cortactin-actin decoupling in GBM43/sgAURKB (P = 0.004) xenografts, but not in GBM43/sgACP1 xenografts (P = 0.2) (lower graph). n = 4/group, original magnification, ×60; scale bar: 20 mm. ns, not significant; *P < 0.05; **P < 0.01. One-way ANOVA with Tukey’s pairwise post hoc comparisons. Scatter dot plots show mean (horizontal bar) with standard deviation (vertical bar).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts